Across TCGA pan-cancer cohorts, GRK3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GRK3 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GRK3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GRK3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.
UCEC, HNSC, and STAD are the cancer types where GRK3 Mutation most reproducibly stratifies survival.